Background: Diabetic patients have risk of kidney disease. The aim of this study was to assess the level of renal risk in our study population and to identify the associated predictive factors. Methods: It was a descriptive and analytical cross-sectional study carried out over 5 years (January 1, 2016 to December 31, 2020). All patients were included regardless of the duration of diabetes and having achieved at least one serum creatinine and at least two (2) proteinuria in the 24 hours over a period of at least three months. The level of renal risk was assessed using the KDIGO 2012 classification. Results: A total of 320 patient medical files were retained. The sex ratio M/F was 1.2. The average age was 57.2 ± 11.8 years. Hypertension was the most common comorbidity (84.4%). Diabetic nephropathy was found in 177 patients, a frequency of 42.8%. The very significant renal risk was found in 174 patients (54.4%). In multivariate logistic regression, the risk factors significantly associated with renal risk were: Male sex (OR = 2.50; 95% CI = 1.29 - 4.84, p-value = 0.006); microangiopathy (OR = 5.54; 95% CI = 1.82 - 16.85 p = 0.002) and beta-blockers (OR = 5.64; 95% CI = 1.04 - 30.53 p = 0.004). The Oral Antidiabetes (OR = 0.23; 95% CI = 0.10 - 0.55, p = 0.001), the blockers of Renin-Angiotensin system (OR = 0.58; 95% CI = 0.41 - 0.90, p = 0.040) and the average socioeconomic level (OR = 0.50; 95% CI = 0.25 - 0.98, p = 0.044) were rather the protective factors.
KeywordsDiabetic Kidney DiseaseKidney RiskTogo
Nemi, K.D., Djalogue, L., Djagadou, K.A., Tchamdja, T., Tsevi, Y.M. and Balaka, A. (2019) Les modes de révélation du diabète sucré au CHU Sylvanus Olympio de Lomé. The Pan African Medical Journal, 34, Article No. 99. https://doi.org/10.11604/pamj.2019.34.99.20012
Cooper-DeHoff, R.M., Gong, Y., Handberg, E.M., Bavry, A.A., Denardo, S.J., Bakris, G.L., et al. (2010) Tight Blood Pressure Control and Cardiovascular Outcomes among Hypertensive Patients with Diabetes and Coronary Artery Disease. JAMA, 304, 61-68. https://doi.org/10.1001/jama.2010.884
Zanchi, A., Lehmann, R. and Philippe, J. (2012) Antidiabetic Drugs and Kidney Disease—Recommendations of the Swiss Society for Endocrinology and Diabetology. Swiss Medical Weekly, 142, w13629. https://doi.org/10.4414/smw.2012.13629
Zanchi, A., Cherpillod, A., Pitteloud, N., Burnier, M. and Pruijm, M. (2014) Insuffisance rénale et diabète: les précautions à prendre. Forum Médical Suisse, 14, 100-104. https://doi.org/10.4414/fms.2014.01761
Ponte, B., Pruijm, M., Marques-Vidal, P., Martin, P.-Y., Burnier, M., Paccaud, F., et al. (2013) Determinants and Burden of Chronic Kidney Disease in the Population-Based CoLaus Study: A Cross-Sectional Analysis. Nephrology Dialysis Transplantation, 28, 2329-2339. https://doi.org/10.1093/ndt/gft206
Black, C., Sharma, P., Scotland, G., McCullough, K., McGurn, D., Robertson, L., et al. (2010) Early Referral Strategies for Management of People with Markers of Renal Disease: A Systematic Review of the Evidence of Clinical Effectiveness, Cost-Effectiveness and Economic Analysis. Health Technology Assessment (Winchester, England), 14, 1-184. https://doi.org/10.3310/hta14210
Gallagher, H. and Suckling, R.J. (2016) Diabetic Nephropathy: Where Are We on the Journey from Pathophysiology to Treatment? Diabetes, Obesity and Metabolism, 18, 641-647. https://doi.org/10.1111/dom.12630
Tsevi, Y., Amekoudi, E.Y.M. and Sabi, T. (2021) Déclin rapide de la fonction rénale chez les patients diabétiques à Lomé (Togo). Néphrologie & Thérapeutique, 17, 310-311. https://doi.org/10.1016/j.nephro.2021.07.166
Gross, J.L., De Azevedo, M.J., Silveiro, S.P., Canani, L.H., Caramori, M.L. and Zelmanovitz, T. (2005) Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care, 28, 164-176. https://doi.org/10.2337/diacare.28.1.164
Definition WHO (2006) Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. World Health Organization, Geneva, 3.
Inker, L.A., Astor, B.C., Fox, C.H., Isakova, T., Lash, J.P., Peralta, C.A., et al. (2014) KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. American Journal of Kidney Diseases, 63, 713-735. https://doi.org/10.1053/j.ajkd.2014.01.416
Eknoyan, G., Lameire, N., Eckardt, K.U., Kasiske, B., Wheeler, D., Levin, A., et al. (2013) KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 3, 5-14.
(1999) 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. Journal of Hypertension, 17, 151-184. https://doi.org/10.1097/00004872-199917020-00001
Sabi, K.A., Noto-Kadou-Kaza, B., Amekoudi, Y.E., Tsevi, M.C., Kossidze, K. and Amedegnato, D. (2014) Profil épidémioclinique des patients en primoconsultation néphrologique au Togo. Médecine et Santé Tropicales, 24, 169-171. https://doi.org/10.1684/mst.2014.0318
Ritz, E. (2011) Limitations and Future Treatment Options in Type 2 Diabetes with Renal Impairment. Diabetes Care, 34, S330-S334. https://doi.org/10.2337/dc11-s242
Molitch, M.E., DeFronzo, R.A., Franz, M. and Keane, W.F. (2004) Nephropathy in Diabetes. Diabetes Care, 27, S79. https://doi.org/10.2337/diacare.27.2007.S79
Brosius, F.C. (2008) New Insights into the Mechanisms of Fibrosis and Sclerosis in Diabetic Nephropathy. Reviews in Endocrine and Metabolic Disorders, 9, 245-254. https://doi.org/10.1007/s11154-008-9100-6
Viberti, G. and Wheeldon, N.M. (2002) Microalbuminuria Reduction with Valsartan in Patients with Type 2 Diabetes Mellitus. Circulation, 106, 672-678. https://doi.org/10.1161/01.CIR.0000024416.33113.0A
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R. andersen, S. and Arner, P. (2001) The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes. New England Journal of Medicine, 345, 870-878. https://doi.org/10.1056/NEJMoa011489
Khochtali, I., Baba, A., Marmouch, H., Hamza, N., Kacem, M. and Mahjoub, S. (2010) P65 Tabac et microalbuminurie chez le diabétique type 2. Diabetes & Metabolism, 36, A55. https://doi.org/10.1016/S1262-3636(10)70213-5
Errahali, Y., Moumen, A., Chakdoufi, S., Guerboub, A.A., El Jadi, H., Meftah, A., et al. (2015) Facteurs associés à la néphropathie diabétique: à propos de 230 cas. Annales d’Endocrinologie, 76, 552. https://doi.org/10.1016/j.ando.2015.07.853
Sanogo, S., Haidara, I., Diallo, M.M., Diallo, A.M. and Nientao, A. (2014) OP81 Etude de l’impact socioéconomique du diabète au CHU Gabriel Touré de Bamako, Mali. Diabetes Research and Clinical Practice, 103, S31. https://doi.org/10.1016/S0168-8227(14)70104-4
Casas, J.P., Chua, W., Loukogeorgakis, S., Vallance, P., Smeeth, L., Hingorani, A.D., et al. (2005) Effect of Inhibitors of the Renin-Angiotensin System and Other Antihypertensive Drugs on Renal Outcomes: Systematic Review and Meta-Analysis. The Lancet, 366, 2026-2033. https://doi.org/10.1016/S0140-6736(05)67814-2
Chanson, P., Timsit, J. and Charbonnel, B. (2000) Données actualisées de l’UKPDS: Implications pour la prise en charge des patients diabétiques de type 2. Médecine Thérapeutique/Endocrinologie, 2, 207-216.
Mohammedi, K. (2016) Bénéfice du traitement intensif précoce du diabète de type 1 sur la mortalité à long terme: nouvelles données de l’étude DCCT/EDIC. Médecine Des Maladies Métaboliques, 10, 33-34. https://doi.org/10.1016/S1957-2557(16)30084-0
Krzesinski, J.-M. (2004) Le medicament du mois: Preterax, la premiere association fixe faiblement dosee contenant un inhibiteur d’enzyme de conversion et un diuretique thiazide. Revue Médicale de Liège, 59, 601-606.
Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B., et al. (2001) Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes. New England Journal of Medicine, 345, 851-860. https://doi.org/10.1056/NEJMoa011303